Professor Clark is widely recognised for his role in the development of the cochlear implant,[1][2] a device that can restore hearing to deaf individuals.

During his tenure, the Institute's research focus expanded to include a variety of clinical areas, such as neurological conditions, blindness, and inflammatory bowel disease.

[3][4][5] Under his leadership, the scope of the Institute's research was broadened to encompass auto-immune, chronic, brain, hearing, and vision disorders.

The second campus exists in the Daly Wing of St Vincent's Hospital, Melbourne which houses the institute's wet labs and device fabrication facilities.

[13] The application of electricity for the purpose of modifying nerve function has emerged as a fundamental method for treating various auto-immune and chronic ailments that have limited responsiveness to traditional pharmaceutical treatments.

Professor Graeme Clark, the founder of the Bionics Institute, played a prominent role in the development of Australia's cochlear implant,[24][25] which was later commercialised by Cochlear Pty Ltd.[26] Building upon this success, the Bionics Institute has also produced several spin-off companies including Epi-Minder, which focuses on the commercialisation of an epilepsy seizure monitoring device;[27][28][29][30] DBS Tech which specialised in adaptive deep brain stimulation systems for Parkinson's disease;[31][32] and Neo-Bionica (launched 2021),[33] a company dedicated to the design and manufacturing of specialised medical devices and implants for human clinical trials.